Rat's Rant: What's hot, what's not and ... more biotech winners
Oct 3, 2019
Oct 3, 2019 |
Immuron’s (ASX:IMC) second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients.
Immuron shares soar more than 20%
Sep 4, 2019
Sep 4, 2019 |
Immuron’s (ASX:IMC) share price has surged on the back of extremely promising clinical results.
Immuron delivers another year of strong sales growth
Sep 2, 2019
Sep 2, 2019 |
Travelan is Immuron’s (ASX:IMC) over-the-counter gastrointestinal and digestive health supplement, and global sales increased by 29.5% year-on-year in fiscal 2019 to $2.39 million.
Immuron’s shares rise on the back of Travelan® results
Jun 12, 2019
Jun 12, 2019 |
Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share price performance on the back of this news.
Digestive health supplement lifts Immuron’s sales
Apr 15, 2019
Apr 15, 2019 |
Immuron Limited (ASX:IMC | NASDAQ:IMRN) third quarter sales for its commercially available products, including Travelan®, surged 66%.